Back to Search
Start Over
Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients
- Source :
- JAAD Case Reports, Vol 6, Iss 2, Pp 99-102 (2020), JAAD Case Reports
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by inflammatory nodules, abscesses, and fistulae. Severe disease is frequently treated with adalimumab or infliximab, but limited research and insurance coverage confine treatment options. Often, aggressive multifaceted therapeutic regimens fail in severe cases. The Janus kinase (JAK) inhibitor, tofacitinib, acts through the JAK-STAT pathway, suppressing inflammatory cytokines implicated in HS pathogenesis, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α.1 JAK inhibitors may benefit HS patients who lack response to targeted biologic therapy. We report on 2 patients with a rare, recalcitrant, ulcerating HS phenotype who, despite not responding to numerous treatments, including biologics (Table I), exhibited prolonged response to a tofacitinib multimodal regimen. Table I Baseline patient characteristics
- Subjects :
- Oncology
HS PGA, Hidradenitis Suppurativa Physician's Global Assessment
medicine.medical_specialty
PG, pyoderma gangrenosum
phenotype
HS, hidradenitis suppurativa
RA, rheumatoid arthritis
Case Report
Dermatology
Proinflammatory cytokine
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Internal medicine
lcsh:Dermatology
medicine
Adalimumab
Hidradenitis suppurativa
TNF, tumor necrosis factor
tofacitinib
Tofacitinib
treatment
business.industry
hidradenitis suppurativa
lcsh:RL1-803
medicine.disease
Infliximab
IL, interleukin
ulceration
030220 oncology & carcinogenesis
Rheumatoid arthritis
Tumor necrosis factor alpha
JAK, Janus kinase
Janus kinase
business
medicine.drug
Subjects
Details
- ISSN :
- 23525126
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- JAAD Case Reports
- Accession number :
- edsair.doi.dedup.....2bf67b0a069580bc5075f452e6667e12
- Full Text :
- https://doi.org/10.1016/j.jdcr.2019.10.010